First imported coccidioidomycosis in Turkey: A potential health risk for laboratory workers outside endemic areas

Kantarcıoğlu, A. Serda; Sandoval-Denis, Marcelo; Aygün, Gökhan; Kiraz, Nuri̇; Akman, Canan; Apaydın, Hülya; Karaman, Emin; Guarro, Josep; Hoog, G.S. de; Gürel, Mehmet Salih

doi:10.1016/j.mmcr.2014.01.002

Cited by 4 publications

(3 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The adverse events (AEs) related to the study medication also included mild dizziness, headache, eye discomfort and fatigue, and occurred along with significantly increased platelet counts above the normal range. Similar findings of headache and dizziness were also reported in previous studies of romiplostim [12][13][14][15] and eltrombopag [13][14][15][16][17][18]. In the eltrombopag study [13][14][15][16][17][18], a 2-4% elevation of aminotransferase was found; individual individuals had an interruption of treatment due to liver toxicity.…”

Section: Discussionsupporting

confidence: 87%

See 1 more Smart Citation

Safety, Pharmacokinetics and Pharmacodynamics of Hetrombopag Olamine, a Novel TPO‐R Agonist, in Healthy Individuals

Liang

Zeng

et al. 2017

Basic Clin Pharma Tox

View full text Add to dashboard Cite

Hetrombopag olamine (hetrombopag) is a novel small-molecule, orally bioavailable, non-peptide thrombopoietin (TPO) receptor agonist that is being developed as the treatment for thrombocytopenia. Two randomized, placebo-controlled phase I studies were conducted in 72 healthy individuals to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of hetrombopag. Hetrombopag was orally administered with a single dose in five dose cohorts (5 mg, 10 mg, 20 mg, 30 mg or 40 mg) in the first study, and given once daily for 10 days in three dose cohorts (2.5 mg, 5.0 mg or 7.5 mg) in the second study, respectively. Hetrombopag was well tolerated, and the majority of adverse events associated with medicine were platelet elevations significantly above the normal range in healthy individuals. The single dose-escalation study revealed a T of approximate 8 hr, and a t of 11.9 hr to 40.1 hr in a dose-prolonged manner. A dose-proportional increase in maximum concentration (C ) of hetrombopag was observed, with area under the curve (AUC) increasing in a greater than dose-proportional manner. The plasma concentration of hetrombopag reached the steady-state after 7 days. The steady-state AUC and C were dose-proportionally elevated from the 5.0 mg to 7.5 mg dose level. The potent pharmacological effect of the hetrombopag-induced platelet elevation was observed in a time- and dose-dependent manner. Furthermore, the thrombopoietic response was significantly (p < 0.0001) correlated to the plasma exposure level of hetrombopag in single and multiple administration studies. Taken together, results of this study support further clinical development of hetrombopag in patients with thrombocytopenia.

show abstract

Section: Discussionsupporting

confidence: 87%

“…Each dose was investigated in a group of six individuals (five on hetrombopag and one on placebo). Plasma samples for PK analysis were collected before dosing and at 1,2,4,6,8,10,12,16,24,48,72,96 and 120 hr after hetrombopag administration.…”

Section: Study Amentioning

confidence: 99%

Safety, Pharmacokinetics and Pharmacodynamics of Hetrombopag Olamine, a Novel TPO‐R Agonist, in Healthy Individuals

Liang

Zeng

et al. 2017

Basic Clin Pharma Tox

View full text Add to dashboard Cite

show abstract

“…after inhalation of airborne arthroconidia (219). Recently, an imported coccidioidomycosis case has been detected in a 41-year-old other-wise healthy Turkish man who visited Texas area in the USA and returned to Turkey (220).…”

Section: Blastomycosis Is a Zoonotic Fungal Infection Caused Bymentioning

confidence: 99%

Overview of Zoonotic Diseases in Turkey: The One Health Concept and Future Threats

İncı¹,

Doğanay²,

Özdarendeli³

et al. 2018

TurkiyeParazitolDerg

View full text Add to dashboard Cite

Zoonotic infections are globally important diseases and lead to huge economic losses in both low-and middle-income and high-income countries. Global warming, environmental and ecological changes, illegal movement of animals and humans, regional civil wars, and poverty are predisposing factors for the emergence of zoonotic infections and their distribution worldwide; they are also a big threat for the future. In addition, environmental pollution and antimicrobial resistance are immense serious threats and dangers to prevent and control zoonotic infections. The natural location of Turkey allows many emerged or re-emerged infections with zoonotic characteristics by animal movements, such as bird immigrations, and by human movements due to civil wars as seen with regional refugees. Numerous zoonotic diseases, including 37 bacterial, 13 fungal, 29 viral, 28 parasitic (3 trematodes, 7 cestodes, 10 nematodes, and 8 protozoan), and totally 107 infections, have been reported from Turkey to date. Additionally, many ectoparasitic zoonoses within 15 different arthropod groups and one leech infestation have been reported from Turkey to date. The "One Health" initiative is particularly relevant for developing strategies to combat zoonotic diseases. In this article, we review the occurrence of zoonotic diseases in man and animals in Turkey in the light of the "One Health" perspective.

show abstract

Primary and Disseminated Cutaneous Coccidioidomycosis: Clinical Aspects and Diagnosis

Arce¹,

Gutiérrez-Mendoza²

2016

Curr Fungal Infect Rep

View full text Add to dashboard Cite

First imported coccidioidomycosis in Turkey: A potential health risk for laboratory workers outside endemic areas

Cited by 4 publications

References 28 publications

Safety, Pharmacokinetics and Pharmacodynamics of Hetrombopag Olamine, a Novel TPO‐R Agonist, in Healthy Individuals

Safety, Pharmacokinetics and Pharmacodynamics of Hetrombopag Olamine, a Novel TPO‐R Agonist, in Healthy Individuals

Overview of Zoonotic Diseases in Turkey: The One Health Concept and Future Threats

Primary and Disseminated Cutaneous Coccidioidomycosis: Clinical Aspects and Diagnosis

Contact Info

Product

Resources

About